Here, we provide evidence that in Burkitt lymphoma the MYC oncogene is a client protein of HSP90, and that MYC expression can be targeted by inhibiting HSP90 function with readily available pharmacologic inhibitors. Here, MYC is linked to Burkitt lymphoma.